Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 9,132 matching trials from the live ClinicalTrials.gov search.

Filters: Tampa, Florida Clear all

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Prurigo Nodularis
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Palo Alto, California • Rancho Santa Margarita, California • Walnut Creek, California + 12 more

Conditions: Conventional Chondrosarcoma
Interventions: INBRX-109, Placebo; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • San Francisco, California + 26 more

Conditions: Alzheimer Disease
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 75 Years and older
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 39
States / cities: Birmingham, Alabama • Sun City, Arizona • Irvine, California + 30 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 884
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more

Conditions: Multiple System Atrophy
Interventions: TEV-56286, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Liver Diseases, Hepatic Impairment
Interventions: PF-07923568; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Tustin, California • Orlando, Florida • Tampa, Florida

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab, cisplatin, IMRT; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 183
States / cities: Anchorage, Alaska • Auburn, California • Burbank, California + 152 more

Conditions: Wounds and Injuries
Interventions: Exufiber Ag+, Exufiber, Aquacel Ag Extra; Device
Lead sponsor: Molnlycke Health Care AB; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Glendale, Arizona • San Francisco, California • Miami, Florida + 5 more

Conditions: Clinical Outcomes
Interventions: Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.; Procedure
Lead sponsor: Foundation for Orthopaedic Research and Education; Other
Eligibility: 21 Years to 100 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Major Depressive Disorder
Interventions: Osavampator, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Oceanside, California • Orange, California • San Jose, California + 21 more

Conditions: HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions: AVZO-021, Fulvestrant, Letrozole, AVZO-023; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more

Conditions: End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions: HEPLISAV-B®; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more

Conditions: Head and Neck Cancer
Interventions: Buparlisib & Paclitaxel; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 21
States / cities: Duarte, California • New Haven, Connecticut • Tampa, Florida + 17 more

Conditions: Decompensated Cirrhosis
Interventions: Emricasan (25 mg), Emricasan (5 mg), Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 76
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
Interventions: Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 86
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more

Conditions: Lower Extremity Injury
Interventions: CBPT, Education Treatment; Other
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 60 Years
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Tampa, Florida • Indianapolis, Indiana • Baltimore, Maryland + 5 more

Conditions: Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rectal Cancer, Rectosigmoid Cancer
Interventions: PINPOINT, SPY Elite; Device
Lead sponsor: Novadaq Technologies ULC, now a part of Stryker; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Concord, California • Los Angeles, California • Orange, California + 18 more

Conditions: Renal Cell Carcinoma
Interventions: TRC105 and Axitinib, Axitinib; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 28
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 23 more

Conditions: B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Years to 39 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more

Conditions: Arteriovenous Fistula
Interventions: AV Fistula creation with sutures, AV Fistula creation with clips; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Tampa, Florida

Conditions: Acute Kidney Injury
Interventions: ABT-719, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 38
States / cities: Danbury, Connecticut • Gainesville, Florida • Jacksonville, Florida + 33 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 111
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Search by objective public record fields.

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Study of INBRX-109 in Conventional Chondrosarcoma

Healthy Aging and Memory Study

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

MAKO-Uni-Knee Arthroplasty Clinical Outcomes and Function

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Improving Recovery After Orthopaedic Trauma: Cognitive-Behavioral Based Physical Therapy (CBPT)

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Continuous Suturing Versus Interrupted Clips for Brachiocephalic AV Fistula Creation

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type